Physician profile
Bryan Cannon
NPI 1265662068
$3,211.81
in general payments reported to CMS, 2019-2025
32 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $250 · 2021: $499 · 2022: $744 · 2023: $701 · 2024: $295 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,337.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $937.18 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $409.93 | 2021-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $360.56 | 2021-2023 | Qulipta, Vraylar, Synthroid |
| Astrazeneca Pharmaceuticals LP | $169.03 | 2019-2021 | |
| Koya Medical, INC. | $167.29 | 2024 | Dayspring, Koya Medical |
| Merck Sharp & Dohme LLC | $167.18 | 2020-2023 | Belsomra, Steglatro |
| Medtronic, INC. | $166.09 | 2022 | |
| Pfizer INC. | $137.48 | 2019-2023 | |
| Glaxosmithkline, LLC. | $128.49 | 2019-2023 | Shingrix, Bexsero, Arexvy |
| Amgen INC. | $89.77 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.34 | 2019 | |
| Eisai INC. | $32.33 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.52 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $28.62 | 2024 | Imcivree |
| Shire North American Group INC | $26.95 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $23.88 | 2022 | |
| Genentech USA, INC. | $23.73 | 2021 | |
| Astellas Pharma US INC | $23.25 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $22.53 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.74 | 2020 | |
| Idorsia Pharmaceuticals US INC | $21.50 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $20.56 | 2023 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $19.34 | 2021 | |
| Edwards Lifesciences Corporation | $18.52 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Janssen Pharmaceuticals, INC | $18.41 | 2019 | |
| Sumitomo Pharma America, INC. | $17.44 | 2023 | Gemtesa |
| Adlon Therapeutics L.P. | $16.73 | 2020 | |
| Corium, LLC | $16.72 | 2023 | Azstarys |
| Currax Pharmaceuticals LLC | $14.93 | 2023 | Contrave |
| Abbott Laboratories | $13.35 | 2023 | Freestyle Libre 2 |
| Amarin Pharma, INC. | $12.79 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Cannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.